PL2007429T3 - Doustna kompozycja o korzystnym działaniu sercowo-naczyniowym, zawierająca berberynę - Google Patents

Doustna kompozycja o korzystnym działaniu sercowo-naczyniowym, zawierająca berberynę

Info

Publication number
PL2007429T3
PL2007429T3 PL07735308T PL07735308T PL2007429T3 PL 2007429 T3 PL2007429 T3 PL 2007429T3 PL 07735308 T PL07735308 T PL 07735308T PL 07735308 T PL07735308 T PL 07735308T PL 2007429 T3 PL2007429 T3 PL 2007429T3
Authority
PL
Poland
Prior art keywords
berberine
oral formulation
activity
cardiovascular effects
beneficial cardiovascular
Prior art date
Application number
PL07735308T
Other languages
English (en)
Inventor
Paolo Senin
Ivo Setnikar
Luigi Angelo Rovati
Original Assignee
Rottapharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Spa filed Critical Rottapharm Spa
Publication of PL2007429T3 publication Critical patent/PL2007429T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL07735308T 2006-03-30 2007-03-29 Doustna kompozycja o korzystnym działaniu sercowo-naczyniowym, zawierająca berberynę PL2007429T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000239A ITTO20060239A1 (it) 2006-03-30 2006-03-30 Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare
EP07735308A EP2007429B1 (en) 2006-03-30 2007-03-29 Oral formulation with beneficial cardiovascular effects, comprising berberine
PCT/IB2007/051109 WO2007113748A1 (en) 2006-03-30 2007-03-29 Oral formulation with beneficial cardiovascular effects, comprising berberine

Publications (1)

Publication Number Publication Date
PL2007429T3 true PL2007429T3 (pl) 2012-07-31

Family

ID=38421558

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07735308T PL2007429T3 (pl) 2006-03-30 2007-03-29 Doustna kompozycja o korzystnym działaniu sercowo-naczyniowym, zawierająca berberynę

Country Status (9)

Country Link
US (1) US9623108B2 (pl)
EP (1) EP2007429B1 (pl)
AT (1) ATE547098T1 (pl)
DK (1) DK2007429T3 (pl)
ES (1) ES2382115T3 (pl)
IT (1) ITTO20060239A1 (pl)
PL (1) PL2007429T3 (pl)
PT (1) PT2007429E (pl)
WO (1) WO2007113748A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100242345A1 (en) 2006-05-19 2010-09-30 LS9, Inc Production of fatty acids & derivatives thereof
US8110670B2 (en) 2006-05-19 2012-02-07 Ls9, Inc. Enhanced production of fatty acid derivatives
JP2011522525A (ja) 2008-05-16 2011-08-04 エルエス９・インコーポレイテッド 炭化水素を製造するための方法および組成物
ITMI20081403A1 (it) 2008-07-29 2010-01-30 Velleja Res Srl Composizioni comprendenti berberina e/o suoi analoghi o estratti che la contengano, per la prevenzione e il trattamento delle alterazioni del quadro lipidico e glucidico
WO2010062480A2 (en) 2008-10-28 2010-06-03 Ls9, Inc. Methods and compositions for producing fatty alcohols
WO2010104595A1 (en) * 2009-03-11 2010-09-16 Xintria Pharmaceutical Corporation, Inc. Methods and compositions for the treatment of metabolic and cardiovascular disorders
BRPI1015313B1 (pt) 2009-04-27 2021-06-01 Genomatica, Inc. Método fermentativo para produzir um éster de ácido graxo empregando um microorganismo geneticamente modificado e método para a produção de ésteres de ácidos graxos
FR2950061B1 (fr) 2009-09-11 2013-12-20 Coatex Sas Monomeres associatifs a base de polycosanols, epaississants associatifs correspondants et leurs utilisations
KR101307051B1 (ko) 2011-05-20 2013-09-11 강릉원주대학교산학협력단 미세조류 단백질 가수분해물을 포함하는 콜레스테롤 강하용 조성물
ITMI20121696A1 (it) * 2012-10-09 2014-04-10 Ddf Group S A S Composizioni per il trattamento delle iperlipidemie
ITMI20130241A1 (it) 2013-02-21 2014-08-22 Andrea Rondi Composizione per il trattamento di disordini metabolici
ITUB20150541A1 (it) 2015-03-03 2016-09-03 Acraf Composizione comprendente sostanze e/o estratti naturali
CN107920561A (zh) * 2015-03-16 2018-04-17 自然阳光产品公司 可用于食品、饮食补充剂、化妆品和药物制剂的呈现多种协同抗氧化剂活性的植物复合物
EP3117825A1 (en) * 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
WO2021090214A2 (en) * 2019-11-04 2021-05-14 Alesco S.R.L. Sucrosomial® berberine, its compositions and their use
IT201900020290A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Berberina sucrosomiale®, sue composizioni e loro uso
IT201900020316A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Uso di berberina sucrosomiale® e sue composizioni nel trattamento di alterazioni del metabolismo glucidico
IT201900020300A1 (it) * 2019-11-04 2021-05-04 Alesco Srl Uso di berberina sucrosomiale® e sue composizioni nel trattamento di dislipidemie
IT202200008537A1 (it) * 2022-04-29 2023-10-29 Neilos S R L “Composizione nutraceutica o farmaceutica per la salute cardiovascolare”
IT202200008534A1 (it) * 2022-04-29 2023-10-29 Neilos S R L “Composizione nutraceutica o farmaceutica per la salute cardiovascolare”
DE202023106947U1 (de) 2023-11-23 2024-01-10 Supett Laboratories Limited Zusammensetzung umfassend Panthenol, PQQ und Quercetin zur Vorbeugung von Herzkrankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952393A (en) 1998-02-12 1999-09-14 Sorkin, Jr.; Harlan Lee Composition for reducing serum cholesterol levels
US6436406B1 (en) 2000-06-15 2002-08-20 A. Glenn Braswell Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
US20030054978A1 (en) 2001-08-31 2003-03-20 Babish John G. Arginine compositions for coordinate modification of multiple cardiovascular risk factors
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
ITTO20040682A1 (it) * 2004-10-07 2005-01-07 Rottapharm S R L Formulazione per somministrazione orale avente un effetto salutistico sull'apparato cardiovascolare

Also Published As

Publication number Publication date
ITTO20060239A1 (it) 2007-09-30
US20090136469A1 (en) 2009-05-28
US9623108B2 (en) 2017-04-18
DK2007429T3 (da) 2012-05-29
EP2007429B1 (en) 2012-02-29
EP2007429A1 (en) 2008-12-31
ES2382115T3 (es) 2012-06-05
PT2007429E (pt) 2012-04-12
ATE547098T1 (de) 2012-03-15
WO2007113748A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
DK2007429T3 (da) Oralt præparat med gavnlige cardiovaskulære virkninger indeholdende berberin
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
MX351584B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral.
EP3626253A3 (en) Stable formulations of linaclotide
WO2011104652A3 (en) Veterinary compositions
WO2012065121A3 (en) Metabolized conditioned growth medium and methods of use
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
WO2008113066A3 (en) Ubiquinol and alpha lipoic compositions
WO2010149727A3 (en) Injectable formulations containing asenapine and method of treatment using same
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
WO2014082027A3 (en) Antioxidant dietary supplement
WO2011149981A3 (en) Oral formulations for counteracting effects of aging
WO2011116220A3 (en) Oral supplement
CY1108314T1 (el) Σκευασμα για στοματικη χορηγηση εχοντας μια δραση που προαγει την υγεια επι του καρδιαγγειακου συστηματος
WO2012145575A3 (en) Therapy for leukemia
WO2010041832A3 (ko) 패 유래 화합물 함유 항산화 활성 조성물
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
CL2012003250A1 (es) Uso de un galactolipido en combinacion con acido ascorbico y/o un derivado del mismo que sirve para proteger una composicion contra la oxidacion; metodo para la preparacion de la composicion, composicion; y producto.
WO2013173803A3 (en) Formulations of amoxicillin and clavulanate potassium and methods for using same
CA2847575C (en) Method for increasing osteoblastic function
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
WO2011092655A3 (en) Mentha suaveolens essential oil and therapeutic activities thereof
WO2012134167A3 (ko) 비파엽 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품